Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.

Siddiqui, M S; Lai, Z M; Spain, L; Greener, V; Turajlic, S; Larkin, J; Morganstein, D L

Siddiqui, M S; Lai, Z M; Spain, L; Greener, V; Turajlic, S; Larkin, J; Morganstein, D L.

Affiliation

Siddiqui MS; Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.
Lai ZM; Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.
Spain L; Skin Unit, Royal Marsden Hospital, London, UK.
Greener V; Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.
Turajlic S; Skin Unit, Royal Marsden Hospital, London, UK.
Larkin J; Skin Unit, Royal Marsden Hospital, London, UK.
Morganstein DL; Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK. d.morganstein@ic.ac.uk.

J Endocrinol Invest ; 44(1): 195-203, 2021 Jan.

Article in En | MEDLINE | ID: mdl-32449093

Subject(s)

Antineoplastic Agents, Immunological/adverse effects; Biomarkers/blood; Hypophysitis/pathology; Ipilimumab/adverse effects; Melanoma/drug therapy; Thyrotropin/blood; Thyroxine/blood; Adult; Aged; Female; Follow-Up Studies; Humans; Hypophysitis/blood; Hypophysitis/chemically induced; Male; Melanoma/pathology; Middle Aged; Prognosis; Retrospective Studies

Key words

Hypophysitis; Ipilimumab; Melanoma; TSH index

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroxine / Thyrotropin / Biomarkers / Hypophysitis / Ipilimumab / Antineoplastic Agents, Immunological / Melanoma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Endocrinol Invest Year: 2021 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google